Brinsupri is their main drug, on pace to be a billion dollar drug, 44% sequential growth, also have Arikayce which grew 6%, much smaller sales total. Has a P3 in FPIP. 1.4 billion in cash, but net loss of 163MM in Q1. CEO has been selling shares. Elevated premium to its peers, will have to execute, expected to be 4 billion in sales by 2029 with a billion in net earnings. Other may be able to add more color to my comments,in viewing my notes current takeaway from latest earnings. Considered a respitory, inflammatory franchise. Will watch, bought a small position so it’s in front of me on the screen. Been waiting for a pullback, like RVMD with the failed takeover attempt, it provided a good opportunity in the low 90’s.